SCHEMBL3393113

SCHEMBL3393113

Cc1ccc(S(=O)(=O)N(CCc2cccc(OCc3ccccc3)c2)C(C)C(=O)O)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.49
CA1 P00915 2/20 0.49
CA2 P00918 2/20 0.49
CA4 P22748 2/20 0.49
CA9 Q16790 2/20 0.49
LTB4R Q15722 1/20 0.48
LTB4R2 Q9NPC1 1/20 0.48
ALOX5 P09917 1/20 0.48
CYP2D6 P10635 1/20 0.47
KEAP1 Q14145 4/20 0.46
NFE2L2 Q16236 3/20 0.46
MMP2 P08253 2/20 0.46
MMP13 P45452 2/20 0.46
CYP4F2 P78329 1/20 0.44
CYP4A11 Q02928 1/20 0.44
PTGES O14684 1/20 0.44
ADAMTS4 O75173 1/20 0.44
MMP14 P50281 1/20 0.44
ADAMTS5 Q9UNA0 1/20 0.44
BCHE P06276 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7888158 1.00 CA12 (0.49) CA12CA1CA2CA4CA9
SCHEMBL3393112 1.00 CA12 (0.49) CA12CA1CA2CA4CA9
SCHEMBL7889204 0.91 CA12 (0.47) CA12CA1CA2CA4CA9
SCHEMBL7879881 0.91 CA12 (0.47) CA12CA1CA2CA4CA9
SCHEMBL13069327 0.89 KEAP1 (0.54) CA12CA1CA2CA4CA9
SCHEMBL3394814 0.88 CA12 (0.48) CA12CA1CA2CA4CA9
SCHEMBL3805084 0.88 CA12 (0.48) CA12CA1CA2CA4CA9
SCHEMBL3394858 0.88 CA12 (0.48) CA12CA1CA2CA4CA9
SCHEMBL18587121 0.81 LTB4R (0.52) LTB4RLTB4R2ALOX5CYP2D6CYP4F2
SCHEMBL3394818 0.80 CA12 (0.49) CA12CA1CA2CA4CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180250308-A1 NR2B SELECTIVE NMDA-RECEPTOR ANTAGONISTS FOR TREATMENT OF IMMUNE-MEDIATED INFLAMMATORY DISEASES WESTFALISCHE WILHELMS-UNIVERSITAT MUNSTER (DE) 2018-09-06 US disclosed
EP-2246331-A1 NR2B-selective NMDA-receptor antagonists Westfälische Wilhelms-Universität Münster (DE) 2010-11-03 EP disclosed
WO-2010122134-A1 NR2B-SELECTIVE NMDA-RECEPTOR ANTAGONISTS Westfälische Wilhelms Universität Münster (DE) 2010-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180250308-A1 NR2B SELECTIVE NMDA-RECEPTOR ANTAGONISTS FOR TREATMENT OF IMMUNE-MEDIATED INFLAMMATORY DISEASES GRIN1, GRIN2B, GRIN3B CA12 2055/4885CA1 1009/4885CA2 3189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.